To study the immunoexpression of the TS, p53, COX2, EGFR, MSH6 and MLH1 biomarkers in patients with colorectal carcinoma; and to make correlations with the degree of cell differentiation, tumor staging and clinical-pathological prognostic factors. This evidence concerns the gene MLH1 and colorectal carcinoma.